{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:13:39Z","timestamp":1780377219122,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,7]]},"DOI":"10.7759\/cureus.61904","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T18:36:00Z","timestamp":1717785360000},"source":"Crossref","is-referenced-by-count":3,"title":["Prognostic Value of Liver Biomarkers in Hepatocellular Carcinoma Patients Undergoing Yttrium 90 Transarterial Radioembolization (TARE): A Retrospective Pilot Study"],"prefix":"10.7759","author":[{"given":"Maria del Pilar","family":"Bayona Molano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kolber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana  V","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad R","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhd Wisam","family":"Alnablsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Pothini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G","family":"Singal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet JM","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al.. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021, 7:6. 10.1038\/s41572-020-00240-3","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis","volume":"77","author":"Singal AG","year":"2022","unstructured":"Singal AG, Zhang E, Narasimman M, et al.. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2022, 77:128-39. 10.1016\/j.jhep.2022.01.023","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5125","article-title":"TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis","volume":"12","author":"Brown AM","year":"2023","unstructured":"Brown AM, Kassab I, Massani M, et al.. TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis. Cancer Med. 2023, 12:2590-9. 10.1002\/cam4.5125","journal-title":"Cancer Med"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.21037\/dmr-22-9","article-title":"The pathogenesis of hepatic fibrosis: basic facts and clinical challenges\u201d\u2014assessment of liver fibrosis: a narrative review","volume":"5","author":"Brol M","year":"2022","unstructured":"Brol M, Drebber U, Luetkens J, et al.. The pathogenesis of hepatic fibrosis: basic facts and clinical challenges\u201d\u2014assessment of liver fibrosis: a narrative review. Dig Med Res. 2022, 5:24.","journal-title":"Dig Med Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c120035","article-title":"Hepatic stellate cells and liver fibrosis","volume":"3","author":"Puche JE","year":"2013","unstructured":"Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol. 2013, 3:1473-92. 10.1002\/cphy.c120035","journal-title":"Compr Physiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2019.01088","article-title":"Preoperative albumin-bilirubin grade combined with aspartate aminotransferase-to-platelet count ratio index predict outcomes of patients with hepatocellular carcinoma within Milan criteria after liver resection","volume":"13","author":"Luo H","year":"2019","unstructured":"Luo H, Li C, Chen L. Preoperative albumin-bilirubin grade combined with aspartate aminotransferase-to-platelet count ratio index predict outcomes of patients with hepatocellular carcinoma within Milan criteria after liver resection. Biosci Trends. 2019, 13:176-81. 10.5582\/bst.2019.01088","journal-title":"Biosci Trends"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson PJ","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, et al.. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015, 33:550-8. 10.1200\/JCO.2014.57.9151","journal-title":"J Clin Oncol"},{"key":"ref8","article-title":"To determine the prognostic value of the albumin-bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma","volume":"12","author":"Khalid MA","year":"2019","unstructured":"Khalid MA, Achakzai IK, Hanif FM, Ahmed S, Majid Z, Luck NH. To determine the prognostic value of the albumin-bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma. Gastroenterol Hepatol Bed Bench. 2019, 12:110-5.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0442","article-title":"Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma","volume":"20","author":"Hu B","year":"2014","unstructured":"Hu B, Yang XR, Xu Y, et al.. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014, 20:6212-22. 10.1158\/1078-0432.CCR-14-0442","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103194","article-title":"GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity","volume":"189","author":"Placke T","year":"2012","unstructured":"Placke T, Salih HR, Kopp HG. GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. J Immunol. 2012, 189:154-60. 10.4049\/jimmunol.1103194","journal-title":"J Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000485396","article-title":"Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review","volume":"44","author":"Zheng J","year":"2017","unstructured":"Zheng J, Cai J, Li H, et al.. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. Cell Physiol Biochem. 2017, 44:967-81. 10.1159\/000485396","journal-title":"Cell Physiol Biochem"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.33160\/yam.2018.12.002","article-title":"Utility and limitation of preoperative neutrophil lymphocyte ratio as a prognostic factor in hepatocellular carcinoma","volume":"61","author":"Uchinaka E","year":"2018","unstructured":"Uchinaka E, Amisaki M, Morimoto M, et al.. Utility and limitation of preoperative neutrophil lymphocyte ratio as a prognostic factor in hepatocellular carcinoma. Yonago Acta Med. 2018, 61:197-203. 10.33160\/yam.2018.12.002","journal-title":"Yonago Acta Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001629","article-title":"Neutrophil-lymphocyte ratio predicts the therapeutic benefit of neoadjuvant transarterial chemoembolization in patients with resectable hepatocellular carcinoma","volume":"32","author":"Hong YM","year":"2020","unstructured":"Hong YM, Cho M, Yoon KT, Ryu JH, Yang KH, Jeon UB, Hwang TH. Neutrophil-lymphocyte ratio predicts the therapeutic benefit of neoadjuvant transarterial chemoembolization in patients with resectable hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2020, 32:1186-91. 10.1097\/MEG.0000000000001629","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.10.014","article-title":"Introduction to the liver imaging reporting and data system for hepatocellular carcinoma","volume":"17","author":"Tang A","year":"2019","unstructured":"Tang A, Singal AG, Mitchell DG, et al.. Introduction to the liver imaging reporting and data system for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2019, 17:1228-38. 10.1016\/j.cgh.2018.10.014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref15","article-title":"Lesson 4: evaluation and staging of liver fibrosis","author":"Cox-North P","year":"2021","unstructured":"Cox-North P. Lesson 4: evaluation and staging of liver fibrosis. Evaluation, Staging, and Monitoring of Chronic Hepatitis C Overview. University of Washington, Seattle, Washington;  2021."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard A","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, et al.. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007, 46:32-6. 10.1002\/hep.21669","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.5852","article-title":"A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts","volume":"31","author":"Malinchoc M","year":"2000","unstructured":"Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000, 31:864-71. 10.1053\/he.2000.5852","journal-title":"Hepatology"},{"key":"ref18","unstructured":"United Network for Organ Sharing. Clerical changes for implementation of adding serum sodium to the MELD score. (2015). Accessed. May 3, 2024: https:\/\/optn.transplant.hrsa.gov\/media\/1575\/policynotice_20151101.pdf."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i34.6261","article-title":"Systemic immune-inflammation index for predicting prognosis of colorectal cancer","volume":"23","author":"Chen JH","year":"2017","unstructured":"Chen JH, Zhai ET, Yuan YJ, et al.. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017, 23:6261-72. 10.3748\/wjg.v23.i34.6261","journal-title":"World J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni R","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010, 30:52-60. 10.1055\/s-0030-1247132","journal-title":"Semin Liver Dis"},{"key":"ref21","article-title":"Using classification and regression trees (CART) in SAS\u00ae enterprise MinerTM for applications in public health","volume":"89","author":"Gordon L","year":"2013","unstructured":"Gordon L. Using classification and regression trees (CART) in SAS\u00ae enterprise MinerTM for applications in public health. SAS Global Forum. 2013, 89:","journal-title":"SAS Global Forum"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50949","article-title":"Albumin-bilirubin (ALBI) score and systemic immune-inflammation indexes used as pretreatment outcome predictors in patients with pancreatic ductal adenocarcinoma undergoing robotic or open whipple procedures: a logistic regression analysis","volume":"15","author":"Mejia A","year":"2023","unstructured":"Mejia A, Vivian E, Shah J, Barrera Gutierrez JC. Albumin-bilirubin (ALBI) score and systemic immune-inflammation indexes used as pretreatment outcome predictors in patients with pancreatic ductal adenocarcinoma undergoing robotic or open whipple procedures: a logistic regression analysis. Cureus. 2023, 15:e50949. 10.7759\/cureus.50949","journal-title":"Cureus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-3731","article-title":"The impact of liver fibrosis on microvascular invasion and prognosis of hepatocellular carcinoma with a solitary nodule: a Surveillance, Epidemiology, and End Results (SEER) database analysis","volume":"9","author":"Lin E","year":"2021","unstructured":"Lin E, Zou B, Zeng G, et al.. The impact of liver fibrosis on microvascular invasion and prognosis of hepatocellular carcinoma with a solitary nodule: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Ann Transl Med. 2021, 9:1310. 10.21037\/atm-21-3731","journal-title":"Ann Transl Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22734","article-title":"Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis","volume":"49","author":"Paradis V","year":"2009","unstructured":"Paradis V, Zalinski S, Chelbi E, et al.. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009, 49:851-9. 10.1002\/hep.22734","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S213432","article-title":"Combination of ALBI And APRI to predict post-hepatectomy liver failure after liver resection for HBV-related HCC patients","volume":"11","author":"Mai RY","year":"2019","unstructured":"Mai RY, Wang YY, Bai T, et al.. Combination of ALBI And APRI to predict post-hepatectomy liver failure after liver resection for HBV-related HCC patients. Cancer Manag Res. 2019, 11:8799-806. 10.2147\/CMAR.S213432","journal-title":"Cancer Manag Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001618","article-title":"Prognostic role of preoperative albumin-bilirubin grade on patients with hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis","volume":"32","author":"Geng L","year":"2020","unstructured":"Geng L, Zong R, Shi Y, Xu K. Prognostic role of preoperative albumin-bilirubin grade on patients with hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020, 32:769-78. 10.1097\/MEG.0000000000001618","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001122","article-title":"Analysis of prognostic factors in patients receiving transarterial radioembolization for unresectable hepatocellular carcinoma","volume":"41","author":"Soydal C","year":"2020","unstructured":"Soydal C, Araz M, Nak D, Akkus P, Baltacio\u011flu MH, Bilgic S, Kucuk NO. Analysis of prognostic factors in patients receiving transarterial radioembolization for unresectable hepatocellular carcinoma. Nucl Med Commun. 2020, 41:73-7. 10.1097\/MNM.0000000000001122","journal-title":"Nucl Med Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060879","article-title":"Prognostic role of albumin, bilirubin, and ALBI scores: analysis of 1000 patients with hepatocellular carcinoma undergoing radioembolization","volume":"11","author":"Antkowiak M","year":"2019","unstructured":"Antkowiak M, Gabr A, Das A, et al.. Prognostic role of albumin, bilirubin, and ALBI scores: analysis of 1000 patients with hepatocellular carcinoma undergoing radioembolization. Cancers (Basel). 2019, 11:10.3390\/cancers11060879","journal-title":"Cancers (Basel)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11729","article-title":"Prognostic significance of pre-surgical combined platelet count and neutrophil-lymphocyte ratio for patients with hepatocellular carcinoma","volume":"33","author":"Uchinaka EI","year":"2019","unstructured":"Uchinaka EI, Amisaki M, Yagyu T, et al.. Prognostic significance of pre-surgical combined platelet count and neutrophil-lymphocyte ratio for patients with hepatocellular carcinoma. In Vivo. 2019, 33:2241-8. 10.21873\/invivo.11729","journal-title":"In Vivo"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4239463","article-title":"Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes after curative resection for hepatocellular carcinoma","volume":"2019","author":"Kabir T","year":"2019","unstructured":"Kabir T, Ye M, Mohd Noor NA, Woon W, Junnarkar SP, Shelat VG. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes after curative resection for hepatocellular carcinoma. Int J Hepatol. 2019, 2019:4239463. 10.1155\/2019\/4239463","journal-title":"Int J Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/255126-prognostic-value-of-liver-biomarkers-in-hepatocellular-carcinoma-patients-undergoing-yttrium-90-transarterial-radioembolization-tare-a-retrospective-pilot-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T18:36:06Z","timestamp":1717785366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/255126-prognostic-value-of-liver-biomarkers-in-hepatocellular-carcinoma-patients-undergoing-yttrium-90-transarterial-radioembolization-tare-a-retrospective-pilot-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.61904","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,7]]}}}